ERBB2 and Decreased total leukocyte count: Compared with that in the HP combined with chemotherapy group, the incidence of grade 3-4 adverse events in the novel anti-HER2 ADCs group was relatively higher, especially for nausea (10.8%), vomiting (10.8%), leukopenia (9.6%), and diarrhea (8.4%).